April 17, 2026 · Form 4 insider transaction
Third Rock Ventures V, L.P. sold 426,005 shares of Rapport Therapeutics, Inc. at $40.32 per share, a transaction worth $17.18M. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 4 days after the transaction.
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 21, 2025, previously adopted by the Reporting Person.; The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).; These shares are directly held by Third Rock Ventures V, L.P. ("TRV V"). The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V and TRV GP V LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.